Related Experiment Video

Updated: Oct 8, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.5K

Vasostatin-1 as a potential novel circulating biomarker in patients with chronic systolic heart failure: A pilot

Giuseppe Pinto1, Barbara Colombo2, Adriano Autieri1

  • 1Heart Failure Unit, Department of Cardiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|January 1, 2022
PubMed

Insights

In chronic systolic heart failure (HF), higher levels of vasostatin-1 (VS-1) and chromogranin A (CgA) indicate increased cardiovascular (CV) events. VS-1 may offer complementary prognostic information alongside NT-proBNP in HF patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Circulating chromogranin A (CgA) levels are elevated in chronic systolic heart failure (HF).
  • Vasostatin-1 (VS-1), a cardioregulatory fragment of CgA, is explored for its prognostic potential in HF.

Purpose of the Study:

  • To assess the role of circulating VS-1 as a prognostic marker in patients with chronic systolic HF.
  • To investigate the relationship between VS-1, CgA, NT-proBNP, and left ventricular ejection fraction (LVEF) in HF.

Main Methods:

  • Plasma levels of CgA and VS-1 were measured in 80 patients with chronic systolic HF.
  • Patients were monitored for cardiovascular (CV) events during follow-up.

Main Results:

  • Higher plasma levels of both CgA and VS-1 were observed in patients who experienced CV events.
  • VS-1 levels correlated with NT-proBNP, but not with LVEF.
  • CgA, NT-proBNP, and age were independent predictors of CV events, while VS-1 was not.

Conclusions:

  • Elevated VS-1 and CgA levels are associated with CV events in chronic systolic HF.
  • VS-1's association with NT-proBNP, but not LVEF, suggests it may provide complementary prognostic data.
  • VS-1 warrants further investigation as a potential biomarker in HF management.
Abstract

Keywords:
Chromogranin AHeart failureNatriuretic peptidesVasostatin-1

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.6K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
96
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
251
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
390
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
553
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
43